Limitations, agreements, and source contact

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome · Source last updated 2014-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

GT60

restrictive Agreement

true

point Of Contact

email

info@corcept.com

organization

Corcept Therapeutics

phone

650-327-3270

title

Medical Director

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice